MINT-LOSARTAN TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

LOSARTAN POTASSIUM

Mevcut itibaren:

MINT PHARMACEUTICALS INC

ATC kodu:

C09CA01

INN (International Adı):

LOSARTAN

Doz:

100MG

Farmasötik formu:

TABLET

Kompozisyon:

LOSARTAN POTASSIUM 100MG

Uygulama yolu:

ORAL

Paketteki üniteler:

30/100/500

Reçete türü:

Prescription

Terapötik alanı:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Ürün özeti:

Active ingredient group (AIG) number: 0127971002; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2015-03-03

Ürün özellikleri

MINT-LOSARTAN
_MINT-LOSARTAN(losartan _
_potassium) _
_Page 1 of 44_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-LOSARTAN
Losartan Potassium Tablets
Tablets, 25 mg, 50 mg and 100 mg, Oral
House Standard
Angiotensin II Receptor Antagonist
MINT PHARMACEUTICALS INC.
6575 Davand Drive
Mississauga, ON Canada L5T 2M3
Date of Initial Authorization:
May 9, 2013
Date of Revision:
April 18, 2023
Submission Control Number: 269236
_MINT-LOSARTAN_
_ _
_(losartan potassium) _
_Page 2 of 44_
_ _
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................
4
1.2
Geriatrics
..............................................................................................................................
4
2
CONTRAINDICATIONS
.............................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.........................................................................
5
4
DOSAGE AND ADMINISTRATION
.............................................................................................
5
4.1
Dosing Considerations
..........................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................